Landsbankinn hf.: S&P revises outlook on Landsbankinn’s covered bonds rating to positive
S&P Global Ratings has today affirmed the credit rating for Landsbankinn’s covered bonds at A and revises outlook from stable to positive.
The rating action follows the announcement on revision of Iceland’s rating outlook to positive from 12 May.
Further information can be found in S&P’s announcement, available on the Bank’s website, www.landsbankinn.com/credit-rating.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Bondholders approve amended terms of the 2024 convertible bonds6.5.2024 18:35:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Bondholders approve amended terms of the 2024 convertible bonds The proposed amendments to the terms of the 2024 convertible bond have been approved by the bondholders and will become binding and effective upon approval by the higher cantonal composition authority. Allschwil, Switzerland – May 6, 2024 Idorsia Ltd. (SIX: IDIA) today announced the positive outcome of a bondholder meeting held at 17:30 CEST on May 6, 2024. The bondholder meeting for holders of Idorsia’s outstanding 2024 convertible bonds (ISIN: CH0426820350) (the Bonds) was held to vote on amendments to the terms of the Bonds. 83.5% of the total outstanding bondholders voted in favor of the amendments proposed by Idorsia – significantly exceeding the required two thirds majority threshold. The approved Bond terms include an amended conversion price of CHF 6.00, extended maturity date of January 17, 2025, and the option to call the Bonds at par, in full or in part, at any time upo
Repurchase of Shares6.5.2024 18:30:00 CEST | Press release
Repurchase of Shares Amsterdam, the Netherlands - Flow Traders Ltd. (Euronext: FLOW) has repurchased 46,070 of its own shares in the period from 29 April 2024 up to and including 3 May 2024 at an average price of €19.57. This is in accordance with the €15 million share buyback extension program originally announced on 27 October 2022, of which the period of execution was announced on 28 July 2023 to be extended by 12 months to 26 October 2024. The consideration of this purchase was €0.9 million. The total number of shares purchased under this program to date is 516,082 shares at an average price of €17.30 for a total consideration of €8.9 million. 2,278,464 shares were held in treasury as of 6 May 2024. Contact Details Flow Traders Ltd. Investors Eric Pan Phone: +31 20 7996180 Email: investor.relations@flowtraders.com About Flow Traders Flow Traders is a leading trading firm providing liquidity in multiple asset classes, covering all major exchanges. Founded in 2004, Flow Traders is a
Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD6.5.2024 18:00:00 CEST | Press release
` Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM – May 6, 2024 – 6:00 PM CET, Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, today announces important progress in its preclinical program targeting Geographic Atrophy (GA), a severe and underserved form of Age-Related Macular Degeneration (AMD). This recently launched program has reached the first step with the identification of 50 targets that have the potential to provide better treatment options for GA. These targets are derived from a cutting-edge CRISPR-based target discovery platform, which consists in a genome-wide screening in a phenotypic cellular assay reflective of GA disease. The preclinical team successfully already confirmed the potential of several of these targets across various relevant in vitro models. Next step is to continue the in vitro validation of the remaining identified targets and start their evaluation in GA ani
Appointment of Mary Ann Packo as CEO of Ipsos in North America6.5.2024 17:45:00 CEST | Press release
Appointment of Mary Ann Packo as CEO of Ipsos in North America Paris, New York - May 6, 2024 - Ipsos, one of the world's leading market research companies, is pleased to announce the appointment of Mary Ann Packo, effective today, as CEO of Ipsos in North America. Reporting to Ben Page, CEO of Ipsos, she joins the Group Management Committee. Mary Ann Packo has been working in the market research industry for over 25 years. She has extensive international experience, particularly in the field of brand building, marketing, advertising, consumer research, digital measurement and advisory services. Prior to joining Ipsos, Mary Ann was a Senior Partner at Hypothesis Group, a premium insights, strategy, and design agency. She began her career in the United States, before moving to Paris in 1995 as Executive Director of a joint venture dedicated to studies for Consumer Goods companies, and whose two shareholders were NFO, one of the leading American marketing research companies, and Ipsos. Ba
Coface records a very good start to the year with a net income of €68.4m, up 11.9%6.5.2024 17:36:00 CEST | Press release
Coface records a very good start to the year with a net income of €68.4m, up 11.9% Paris, 6 May 2024 – 17.35 Turnover: €464m, down -1.6% at constant FX and perimeterTrade credit insurance premiums decreased by -3.3%; growth in client activities was nil at the start of the year, after a negative H2-23Client retention still high (93.8%) but down from records; pricing effect remained negative (-1.3%)Double-digit growth in business information (+21.6% at constant FX) and debt collection (+24.1%); factoring down by -6.3%Net loss ratio at 35.8%, improved by 4.9 ppts; net combined ratio at 63.1%, improved by 3.2 pptsGross loss ratio at 33.2%, improved by 7.5 ppts with stable opening year reserving and high reserve releasesNet cost ratio up by 1.6 ppt to 27.3%, reflecting lower revenues and continued investments partially offset by better product mixNet income (group share) at €68.4m, up +11.9% compared to Q1-23Annualised RoATE1 at 14.8% Unless otherwise indicated, change comparisons refer to